Ms. Christina Cameron reports

CONAVI MEDICAL CORP. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS

Conavi Medical Corp. has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario in connection with an offering of common shares of the company and/or prefinanced common share purchase warrants of the company in lieu of common shares.

The offering is expected to be completed on a commercially reasonable efforts agency basis pursuant to an agency agreement to be entered into between the company and Bloom Burton Securities Inc. The number of securities to be distributed, the size of the offering and the price of each common share and prefinanced warrant will be determined by negotiation between the company and Bloom Burton in the context of the market with final terms to be determined at the time of pricing.

The company intends to use the net proceeds from the offering to obtain United States FDA (Food and Drug Administration) 510(k) clearance of the next generation Novasight Hybrid system, as well as complete a limited market release and initiate a broader commercial launch in the United States. The company also intends to use the net proceeds for working capital and other general corporate purposes.

The offering is expected to close on or about Dec. 12, 2025, or such later date as may be agreed upon by the company and Bloom Burton. The offering is subject to the company and the agent entering into a definitive agency agreement, and subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange.

In addition, the securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws.

Access to the preliminary prospectus and any amendments to such document will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The preliminary prospectus is accessible on SEDAR+. Alternatively, an electronic or paper copy of the preliminary prospectus and any amendment to such document may be obtained without charge, from the agent by e-mail at ECM@bloomburton.com, by telephone at 416-640-7585 or by providing the contact with an e-mail address or address, as applicable. The preliminary prospectus contains important, detailed information about the company and the offering. Prospective investors should read the preliminary prospectus before making an investment decision.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid system has regulatory clearance in the United States, Canada, China and Japan.

We seek Safe Harbor.